{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:05:58Z","timestamp":1792292758242,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T00:00:00Z","timestamp":1515974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T00:00:00Z","timestamp":1515974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R34 AG049652"],"award-info":[{"award-number":["R34 AG049652"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG037561"],"award-info":[{"award-number":["R01 AG037561"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13195-017-0332-0","type":"journal-article","created":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T12:14:37Z","timestamp":1516018477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Data-driven identification of endophenotypes of Alzheimer\u2019s disease progression: implications for clinical trials and therapeutic interventions"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2956-6676","authenticated-orcid":false,"given":"Nophar","family":"Geifman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lon S.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Buchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Diaz","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,15]]},"reference":[{"issue":"4","key":"332_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37.","journal-title":"Alzheimers Res Ther"},{"key":"332_CR2","unstructured":"PhRMA - Pharmaceutical Research and Manufacturers of America. Researching Alzheimer\u2019s Medicines: Setbacks and Stepping Stones. 2012. Available from: \n                    http:\/\/phrmadocs.phrma.org\/sites\/default\/files\/pdf\/alzheimersetbacksreport.pdf\n                    \n                  ."},{"issue":"6","key":"332_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","volume":"26","author":"D Mehta","year":"2017","unstructured":"Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin Investig Drugs. 2017;26(6):735\u20139.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"332_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jalz.2013.03.003","volume":"10","author":"RE Kennedy","year":"2014","unstructured":"Kennedy RE, Cutter GR, Schneider LS. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease. Alzheimers Dement. 2014;10(3):349\u201359.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"332_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1212\/WNL.0000000000001376","volume":"84","author":"LS Schneider","year":"2015","unstructured":"Schneider LS, Kennedy RE, Wang G, Cutter GR. Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology. 2015;84(11):1121\u20137.","journal-title":"Neurology"},{"issue":"11","key":"332_CR6","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356\u201364.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"332_CR7","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412\u20134.","journal-title":"Neurology"},{"issue":"3","key":"332_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatric Res"},{"issue":"7","key":"332_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939\u201344.","journal-title":"Neurology"},{"key":"332_CR10","unstructured":"lcmm: Extended Mixed Models Using Latent Classes and Latent Processes. \n                    https:\/\/cran.r-project.org\/web\/packages\/lcmm\/index.html"},{"key":"332_CR11","doi-asserted-by":"crossref","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. arXiv preprint arXiv:1406.5823. 2014.","DOI":"10.18637\/jss.v067.i01"},{"issue":"3","key":"332_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack Jr CR, Jagust WJ, Shaw LM, Toga AW, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201\u20139.","journal-title":"Neurology"},{"issue":"6","key":"332_CR13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","volume":"77","author":"M Sano","year":"2011","unstructured":"Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77(6):556\u201363.","journal-title":"Neurology"},{"issue":"17","key":"332_CR14","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1001\/jama.2010.1510","volume":"304","author":"JF Quinn","year":"2010","unstructured":"Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack Jr CR, Weiner M, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010;304(17):1903\u201311.","journal-title":"JAMA"},{"issue":"8","key":"332_CR15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jama.283.8.1007","volume":"283","author":"RA Mulnard","year":"2000","unstructured":"Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000;283(8):1007\u201315.","journal-title":"JAMA"},{"issue":"15","key":"332_CR16","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jama.300.15.1774","volume":"300","author":"PS Aisen","year":"2008","unstructured":"Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300(15):1774\u201383.","journal-title":"JAMA"},{"issue":"21","key":"332_CR17","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","volume":"289","author":"PS Aisen","year":"2003","unstructured":"Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289(21):2819\u201326.","journal-title":"JAMA"},{"issue":"16","key":"332_CR18","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1212\/WNL.0b013e318216eb7b","volume":"76","author":"MS Rafii","year":"2011","unstructured":"Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS. Alzheimer's Disease Cooperative S. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76(16):1389\u201394.","journal-title":"Neurology"},{"issue":"8","key":"332_CR19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","volume":"68","author":"PN Tariot","year":"2011","unstructured":"Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011;68(8):853\u201361.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"332_CR20","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1212\/WNL.54.3.588","volume":"54","author":"PS Aisen","year":"2000","unstructured":"Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000;54(3):588\u201393.","journal-title":"Neurology"},{"issue":"7","key":"332_CR21","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1212\/WNL.44.7.1215","volume":"44","author":"D Jacobs","year":"1994","unstructured":"Jacobs D, Sano M, Marder K, Bell K, Bylsma F, Lafleche G, Albert M, Brandt J, Stern Y. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology. 1994;44(7):1215\u201320.","journal-title":"Neurology"},{"issue":"9","key":"332_CR22","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1212\/WNL.42.9.1689","volume":"42","author":"JA Mortimer","year":"1992","unstructured":"Mortimer JA, Ebbitt B, Jun SP, Finch MD. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology. 1992;42(9):1689\u201396.","journal-title":"Neurology"},{"issue":"3","key":"332_CR23","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/jnnp.2005.072306","volume":"77","author":"N Scarmeas","year":"2006","unstructured":"Scarmeas N, Albert SM, Manly JJ, Stern Y. Education and rates of cognitive decline in incident Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2006;77(3):308\u201316.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"332_CR24","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.1073\/pnas.92.11.4725","volume":"92","author":"WJ Strittmatter","year":"1995","unstructured":"Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A. 1995;92(11):4725\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"332_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000093316","volume":"22","author":"T Kleiman","year":"2006","unstructured":"Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, Macavoy M, Gelernter J, van Dyck C. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Dement Geriatr Cogn Disord. 2006;22(1):73\u201382.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"6","key":"332_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000111081","volume":"24","author":"L Bracco","year":"2007","unstructured":"Bracco L, Piccini C, Baccini M, Bessi V, Biancucci F, Nacmias B, Bagnoli S, Sorbi S. Pattern and progression of cognitive decline in Alzheimer's disease: role of premorbid intelligence and ApoE genotype. Dement Geriatr Cogn Disord. 2007;24(6):483\u201391.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"332_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13195-017-0237-y","volume":"9","author":"N Geifman","year":"2017","unstructured":"Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. Alzheimers Res Ther. 2017;9(1):10.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"332_CR28","doi-asserted-by":"publisher","first-page":"e1001602","DOI":"10.1371\/journal.pmed.1001602","volume":"11","author":"D Vistisen","year":"2014","unstructured":"Vistisen D, Witte DR, Tabak AG, Herder C, Brunner EJ, Kivimaki M, Faerch K. Patterns of obesity development before the diagnosis of type 2 diabetes: the Whitehall II cohort study. PLoS Med. 2014;11(2):e1001602.","journal-title":"PLoS Med"},{"issue":"6","key":"332_CR29","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/all.12134","volume":"68","author":"N Lazic","year":"2013","unstructured":"Lazic N, Roberts G, Custovic A, Belgrave D, Bishop CM, Winn J, Curtin JA, Hasan Arshad S, Simpson A. Multiple atopy phenotypes and their associations with asthma: similar findings from two birth cohorts. Allergy. 2013;68(6):764\u201370.","journal-title":"Allergy"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-017-0332-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-017-0332-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-017-0332-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T11:29:51Z","timestamp":1589542191000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-017-0332-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,15]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["332"],"URL":"https:\/\/doi.org\/10.1186\/s13195-017-0332-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,15]]},"assertion":[{"value":"27 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No non-financial conflicts of interest exist for any of the authors.Within 3\u00a0years of the beginning of this work, LSS has received grant and research support from Biogen, Genentech, Johnson & Johnson, Eli Lilly, Lundbeck, Novartis, Roche, Tau Rx and NIH; and has served as a consultant for, and received consulting fees from, AC Immune, Axovant, Cerespir, Cognition, Insys, Johnson & Johnson, Merck, Novartis, Octapharma, Pfizer, Roche, Takeda, Tau Rx, Toyama, vTv and Zinfandel.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"4"}}